Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic eff...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/506442 |
| _version_ | 1819026109334814720 |
|---|---|
| author | Alyssa Schlotman Adam Stater Kyle Schuler Judd Heideman Vandana Abramson |
| author_facet | Alyssa Schlotman Adam Stater Kyle Schuler Judd Heideman Vandana Abramson |
| author_sort | Alyssa Schlotman |
| collection | DOAJ |
| description | A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature. |
| first_indexed | 2024-12-21T05:21:21Z |
| format | Article |
| id | doaj.art-7fd6127a5fc9482abb6f973962f2e6ef |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-21T05:21:21Z |
| publishDate | 2020-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-7fd6127a5fc9482abb6f973962f2e6ef2022-12-21T19:14:47ZengKarger PublishersCase Reports in Oncology1662-65752020-03-0113130430810.1159/000506442506442Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case ReportAlyssa SchlotmanAdam StaterKyle SchulerJudd HeidemanVandana AbramsonA 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.https://www.karger.com/Article/FullText/506442hepatotoxicitybreast cancerfulvestrant |
| spellingShingle | Alyssa Schlotman Adam Stater Kyle Schuler Judd Heideman Vandana Abramson Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report Case Reports in Oncology hepatotoxicity breast cancer fulvestrant |
| title | Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report |
| title_full | Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report |
| title_fullStr | Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report |
| title_full_unstemmed | Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report |
| title_short | Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report |
| title_sort | grade 3 hepatotoxicity following fulvestrant palbociclib and erdafitinib therapy in a patient with er positive pr negative her2 negative metastatic breast cancer a case report |
| topic | hepatotoxicity breast cancer fulvestrant |
| url | https://www.karger.com/Article/FullText/506442 |
| work_keys_str_mv | AT alyssaschlotman grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport AT adamstater grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport AT kyleschuler grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport AT juddheideman grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport AT vandanaabramson grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport |